major resistance mechanism appears to be acquisition of secondary mutations in FLT3, which interfere with the ability of small molecule inhibitors to bind to FLT3 (4, 5) . One strategy to overcome resistance to FLT3 inhibitors in the clinic is to combine them with chemotherapy despite the recognition that chemotherapy is poorly tolerated (6, 7). G1 by sequestering E2F proteins that are required for initiation of S phase. p16
INK4a is a member of the INK4 family of CDK4 cellular inhibitors (10-13) and a tumor suppressor. The genes for Rb and p16 INK4a are frequently deleted or silenced in various types of cancer.
Although mutations in Rb and p16 INK4a are rare in AML patients, p15 INK4b , another member of the INK4 family, has been reported to be down regulated in up to 60% of AML patients (14, 15) ,
indicating an important role of CDK4 in AML. Recently, a selective CDK4 inhibitor PD 0332991
has entered clinical trials and showed promising anti-cancer efficacy in advanced breast cancer patients (16, 17) . Anti-cancer activity of PD 0332991 has also been reported in clinical and preclinical studies of other cancer types including AML (18) (19) (20) (21) . Here, we report the preclinical evaluation of a FLT3/CDK4 dual kinase inhibitor AMG 925. We believe that combined inhibition of two essential kinases by AMG 925 has potential to reduce development of drug resistance in AML patients.
Materials and Methods
Compounds. AMG 925 (2-(2-((9-(trans-4-methylcyclohexyl)-9H- temperature and stopped by adding 20 μL of 20 mM EDTA and 4 nM LANCE Eu-W1024 antiphospho-tyrosine antibody in LANCE detection buffer (PerkinElmer). The plates were incubated at room temperature for 2 h after addition of detection reagents and were then read on an Envision multimode reader (PerkinElmer). Fluorescence signals were measured at 615 nm (8.5-nm bandwidth) and 665 nm (7.5-nm bandwidth) with a 60 μs delay after excitation at 320 nm (75-nm bandwidth). The signal ratio at 665/615 nm was used in all data analyses. after addition of compounds for determination of P-STAT5 and P-Rb respectively using kits from Meso Scale Discovery (Rockville, MD; Cat# K150IGD-1 for P-STAT5 and Cat# K150ITD-1 for P-Rb).
To determine P-STAT5 or P-Rb in xenograft tumor samples, tumors were allowed to grow to 200-250 mm 3 before administration of AMG 925 via oral gavages. The tumor samples were dissected and snap frozen at different time points after dosing, and the lysates prepared and assayed for levels of P-STAT5 and P-Rb similarly as for cultured cells. ROIs over the dorsal and ventral images and taking the sum of these images (whole body BLI).
The bottom 5 and top 5 animals in the sort were excluded from the study. The remaining mice were rank random assigned to therapeutic groups to achieve 5 groups of (n = 10) with equivalent whole body tumor burden. Treatments were initiated on day 7 and continued for 10 consecutive days. Twice daily (BID) doses were administered 6 h apart. After completion of the treatments mice were monitored for either development of hind limb paralysis (HLP) that resulted from disease progression and >20% body weight loss. Mice were humanely sacrificed using CO 2 asphyxiation and cervical dislocation in accordance with Amgen IACUC criteria. As shown in Figure 1C , AMG 925 induced G1 arrest in Rb + MOLM13, U937 and Colo205. In contrast, AMG 925 did not cause G1 arrest in Rb -MDA-MB-468, which is consistent with the growth inhibition potency of AMG 925 in these cell lines (Table 1 ).
Pharmacokinetic analysis showed that AMG 925 was orally available with a half-life appropriate for twice daily dosing in preclinical animals (Supplementary Figure S1) . respectively during isolation for resistance to sorafenib. We found that AMG 925 inhibited growth of both sorafenib-resistant AML cell lines with potency comparable to those of the parental cell lines MOLM13 and Mv4-11 (Table 1) . Growth inhibition of MOLM13sr and Mv4-11sr by AMG 925 is believed to be primarily through FLT3, which is supported by potent inhibition of P-STAT5 by AMG 925 in the cells (Table 1) . This is also supported by dose 
dependent induction of apoptosis by AMG 925 in the MOLM13sr cells, which was correlated with inhibition of P-FLT3 and P-STAT5 ( Figure 1B) . Sorafenib, however, caused only background level of apoptosis and was much less potent in inhibiting P-FLT3 or P-STAT5 than AMG 925. Similar effects were observed in Mv4-11sr (our unpublished observations).
AMG 925 inhibits growth of subcutaneous MOLM13 xenograft tumors. MOLM13
tumor bearing mice were dosed twice daily by oral administration 6 h apart with 12.5, 25 or 37.5 mg/kg AMG 925. Tumors were then harvested 3, 9, 12 and 24 h after the first dose, and analyzed for levels of P-STAT5 and P-Rb. Maximum inhibition of P-STAT5 and P-Rb was achieved at 6 h and 12 h respectively at the 37.5 mg/kg dose of AMG 925 ( 
evidence that acquired resistance mutations are primary cause of relapse in AML following FLT3 inhibitor treatments (3). All of the relapsed patients from AC220 treatment had acquired mutations in FLT3 that were not detected before the treatment and were confirmed to confer resistance to FLT3 inhibitors including AC220 in vitro. Considering the high intrinsic genetic instability and heterogeneity of AML cells, it is now generally believed that FLT3 specific inhibitors need to be combined with other therapies to achieve the desired clinical efficacy (2).
Combinations with chemotherapy have been tested with some FLT3 inhibitors like sorafenib.
The combination treatments, however, have met with only moderate success primarily due to combined toxicity (6, 7). 
potential advantage of AMG 925 over combining a FLT3 inhibitor with chemotherapy is that the CDK4 inhibiting activity of AMG 925 may be better tolerated based on the KO phenotype of these individual targets in mice (26, 27) and clinical trial results of the CDK4 inhibitor PD0332991 (28) . AMG 925 may also be efficacious as a treatment for AML patients refractory to or relapsed from chemotherapy.
The sequence of treatments for a combination therapy of cancer can sometimes be critical to efficacy. For example, agents causing G1 arrest of the cell cycle are known to protect cancer cells from chemotherapies (29, 30) . In contrast, it has been reported that CDK4 and FLT3 inhibitors, when added simultaneously to AML cells, acted cooperatively in inhibiting AML cell growth and inducing apoptosis (20) . This result was confirmed in our experiments (our unpublished observations). Furthermore, we pre-treated MOLM13 cells with CDK4 inhibitor PD 0332991 for 24 h to arrest cells in G1 and then determined the effect on cell proliferation of FLT3 inhibition by sorafenib. We did not detect significant effect on the sensitivity of MOLM13 to sorafenib (our unpublished observations). However, we could not exclude the possibility that longer G1 arrest would eventually lead to decreased response to FLT3 inhibitors.
Analysis of relapsed AML in AC220-treated patients has confirmed two hot spots for resistance mutations in FLT3-ITD, tyrosine-kinase domain residue D835 and gatekeeper residue F691 (3) . Accumulating published data suggests that FLT3 inhibitors may largely fall into two groups, one represented by AC220 and sorafenib, the other by sunitinib (31) (32) (33) mct.aacrjournals.org
